
Consultant Medical Oncologist in Genito-Urinary tumours @RoyalMarsdenNHS
London, England
Joined September 2017
- Tweets222
- Following887
- Followers448
- Likes1.9K
Daniele Raggi retweeted
10 Must-Read Posts in GU Oncology | November 1–7, 2026
The first week of November brought new research across GU oncology, covering clinical trials, molecular findings, diagnostic approaches, and survivorship care.
This week's selection includes updates on:
▫️ PIONEER+: Clinical trial eligibility among 32,585 patients with metastatic hormone-sensitive prostate cancer.
▫️ RMC-COMPASS: Development and internal validation of a prognostic model for SMARCB1-deficient renal medullary carcinoma.
▫️ Long-term survivorship care for adolescents and young adults with testicular cancer.
▫️ FTO-mediated glycolytic metabolism and immune evasion in papillary renal cell carcinoma.
▫️ Clinicopathological characteristics and outcomes of TFE3-rearranged renal cell carcinoma.
▫️ ENERGIZE: Perioperative nivolumab plus chemotherapy did not meet either co-primary endpoint in muscle-invasive bladder cancer.
▫️ AI-based prediction of potential drug combinations for FGFR-altered urothelial carcinoma.
▫️ MRUSuNet: Combining MRI and ultrasound using AI for clinically significant prostate cancer detection.
▫️ Risk of developing bladder cancer following de novo urothelial atypia, including a 5-year incidence of 6.5% in patients with atypia of unknown significance.
▫️ APCCC 2026: Consensus report on high-risk localized, locally advanced, and biochemically recurrent prostate cancer.
Takeaway: These posts highlight developments in prognostic assessment, molecular research, treatment strategies, diagnostic innovation, and survivorship across GU oncology.
@JGomezRivas @PavlosMsaouel @DanieleRaggi83 @VPasoglou @drenriquegrande @RusuMirabela @LauraBukavinaMD @nealshore
oncodaily.com/genitourinary-…
#OncoDaily #GUOncology
Daniele Raggi retweeted
📣 Latest Article Online! - New Frontiers in Oncology
🩺 Cured but What’s Next? Rethinking Survivorship Care for Adolescent and Young Adult Testicular Cancer Survivors by Daniele Raggi...Anna Patrikidou et al
buff.ly/kLwM9G9
✨ We thank all the authors for your valuable contribution!
@GustaveRoussy
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@DaveDandrea
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
Daniele Raggi retweeted
And that’s a wrap on #ESMO26! 🙌
From packed presentation halls to discussions about the latest data, there has been plenty to take in.
Also a great opportunity to catch up with Dr. Daan De Maeseneer and Dr. Daniele Raggi, two GU oncology experts, and hear their perspectives on some of the highlights from this year’s meeting.
A perfect way to wrap up a busy and inspiring few days. Until next time, ESMO! 👋
Daniele Raggi retweeted
🔥 So proud of @MatteoMNaldini presenting our work at #ESMO26
Spatial profiling of eTNBC from NeoTRIP reveals CD204+ M2 macrophages predict poor chemo-IO response, interact with immunosuppressive cells & accumulate carboplatin
Another contribution toward precision immunotherapy
Daniele Raggi retweeted
As discussed at #ESMO26, data on EV+P in bladder cancer with variant histology remain limited.
Together with Emory and Dr. Jacqueline Brown, we’re studying EV+P in tumors with aberrant histologic features including with squamous, plasmacytoid, and glandular features.
MSK PI: Dr. Sam Funt.
@OncoAlert
More info here: mskcc.org/cancer-care/clinic…
clinicaltrials.gov/study/NCT…
#bladdercancer #esmo2026
Daniele Raggi retweeted
Here the 50+ ADCs that will be discussed at #ESMO26 next week, divided by payload class and target.
B7-H3 TOPO1i leads, with 7 different ADCs!
(Note: TiP and ePoster not included)
Daniele Raggi retweeted
Our #ZZFIRST trial is out today in @NatureMedicine! An academic randomized phase II trial of Talazoparib + Enzalutamide in high-volume mHNPC integrating spatial transcriptomics on longitudinal tumor biopsies. Thanks to all patients and funding from DoD/CDMRP + @ContraCancerEs
Daniele Raggi retweeted
Happy to share our new paper in Clinical Cancer Research on NECTIN4 as a biomarker for enfortumab vedotin in urothelial cancer! @CCR_AACR @AACR
An important clue was already present in EV-301: patients with higher NECTIN4 IHC (H-score >150) had an ORR of 45.8% vs 20.0% with lower expression.
We now take this one step further and show that localization matters:
🎯 Membranous NECTIN4 correlates with EV response — cytoplasmic NECTIN4 does not.
This makes biological sense for an ADC: EV needs to bind its target on the tumor-cell surface to internalize and deliver its payload.
We further integrate NECTIN4 amplification + membranous protein expression, moving toward a more precise biomarker framework for EV.
For ADC biomarkers, it is not simply whether a target is expressed — but how much, where, and in which tumor lesion.
Hopefully another step toward precision ADC therapy in urothelial cancer.
Thanks to a great team and my collaborators! @Markuseckstein3 @KuppeChristoph @braegelmannlab @JoshMeeks @HolzelMichael
aacrjournals.org/clincancerr…
@OncoAlert @weoncologists @DrChoueiri
@Uroweb @AmerUrological @ASCO @PathSoc @OncoAlert @Histo_Journal @andreanecchi @emanuele_crupi @danieleraggi83 @raffcolo @Dr_Aggen @DrRosenbergMSK @h_alahmadie @PGrivasMDPhD @shilpaonc @drenriquegrande @amerseburger @brookmans76 @DrYukselUrun @onkowissen @imedverse @UroDocAsh @urotoday @EUplatinum @JCO_ASCO @CCR_AACR @niklas_kluemper @DrRosenbergMSK @Dr_Aggen @Uromigos @tompowles1 @shilpaonc @PGrivasMDPhD
Daniele Raggi retweeted
Great to see progress in #testicularcancer as reported by @DanieleRaggi83 @royalmarsdenNHS. Compelling data for miR-371a-3p via studies done through @SWOG/@CDNCancerTrials. Excited to see EU-grant funded work in TRANSCEND-XR. @gbanna74 @ravikanesvaran #IUCS26
Daniele Raggi retweeted
Great talk @urologysummit by @DanieleRaggi83 @royalmarsdenNHS on germ cell tumours. Who needs more treatment? Who needs less? Can we stratify and minimise follow up scans after completing the OTIS-S trial? #IUCS26
Daniele Raggi retweeted
With EV+pembrolizumab broadly effective, do we now need biomarkers to identify who benefits most, or who can safely receive less?
The key question is no longer only “who is high risk?” but “who still has disease?”
ctDNA may help move bladder cancer from static risk groups toward real-time treatment decisions.
Excellent presentation by @PGrivasMDPhD at #IUCS26
@neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @yekeduz_emre @ONCOassist
Daniele Raggi retweeted
Science by day, friendship by the lake. 🌿
@gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @PGrivasMDPhD @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @yekeduz_emre @ONCOassist
Daniele Raggi retweeted
🚨 Out now in European Urology Oncology: our real-world landscape of actionable alterations in advanced urothelial carcinoma. Open access. 🔬
Short version: actionable findings are the rule. Acting on them is the exception.
📊 MIER cohort (n=233 MIBC/mUC, TSO500, expert-annotated):
🧬 97% carried at least one pathogenic or likely pathogenic variant (226/233).
🎯 Actionable FGFR3 alterations in 11%, mostly S249/R248 hotspots, all PCR-confirmed.
🧪 40% harboured alterations in 24 biomarkers linked to FDA-approved therapies. PIK3CA 20%, ATM 6.4%, KRAS 5.2%.
📈 ERBB2 amplification in 15% (36/233), HER2 IHC 3+ in 15 patients.
⚠️ MSI-high by NGS in 4.2%, but only 4 of 9 showed MMR protein loss on IHC. Orthogonal validation is not optional.
🧩 Pathway level: cell cycle 82% (TP53 73%, RB1 25%), RTK/Ras/PI3K 42%, histone modifiers 47% (KDM6A 25%), SWI/SNF 27%.
📉 Then the MTB cohort (n=40, routine diagnostics, CCC Erlangen-EMN):
55% had actionable alterations. 5% on-label, 50% off-label.
One patient received the recommended therapy. 🩺
ERBB2 amplification plus PIK3CA mutation, off-label alpelisib, stable disease and pain improvement for 4 months, then progression and skin toxicity. A second patient qualified for trastuzumab deruxtecan on cooccurring ERBB2 amplification and IHC 3+, but died before treatment could start.
Retrospectively, 80% of the MIER cohort would have had an indication. 10% on-label, 70% off-label.
That gap is the finding. 🧠
Four things I take from it:
1️⃣ The bottleneck has moved. We are no longer short of targets. We are short of access, evidence, and workable pathways. Cost coverage, comorbidity, and patient deterioration between recommendation and administration prevented most indications. Discovery papers keep counting alterations; almost nobody counts what happens next.
2️⃣ Off-label is not a free option. Seventy percent theoretical eligibility sounds impressive until you ask what the evidence behind each recommendation actually is. Much of it is early-phase or preclinical. Advancing those cautiously is not timidity, it is the correct reading of the data.
3️⃣ Genomics without protein-level validation has limits. Not every alteration translates into an expressed, targetable protein on the cell surface. For ADCs that distinction is everything, which is why membranous target assessment belongs alongside sequencing rather than after it.
4️⃣ Timing decides relevance. In Germany, MTB referral typically happens after progression on EV(P) and, per FDA label, trastuzumab deruxtecan. By then Nectin-4 and HER2 testing no longer changes anything. That pushes interest toward TROP2, HER3/EGFR and newer constructs. Most of these agents are inaccessible outside trials, which makes trial referral one of the most valuable things an MTB can offer.
Our turnaround is 6 to 40 days, median 11 to 18. That is fast enough. The delay is not analytical. It is structural. 🔬
With the German Model Project Genome Sequencing now underway, this is exactly the moment to measure implementation, not just actionability.
Huge credit to first author Maria Giulia Carta and to Fulvia Ferrazzi, co-senior with me, and to the whole Erlangen team. @FulviaFerrazzi
🔗 doi.org/10.1016/j.euo.2026.0…
@Uroweb @AmerUrological @ASCO @PathSoc @OncoAlert @Histo_Journal @niklas_kluemper @andreanecchi @emanuele_crupi @danieleraggi83 @raffcolo @Dr_Aggen @DrRosenbergMSK @h_alahmadie @PGrivasMDPhD @shilpaonc @drenriquegrande @amerseburger @brookmans76 @DrYukselUrun @onkowissen @imedverse @UroDocAsh @IBCG_BladderCA @AndreaNecchi @apolo_andrea @PGrivasMDPhD
#Uropathology #urothelial #BladderCancer #PrecisionOncology #pathtwitter
Daniele Raggi retweeted
Very sad to be saying goodbye to the very lovely and hard working @drmaneesh_singh after a year @royalmarsdenNHS. We have loved working with you, come back soon! Thanks to @VedangMurthy and @docpriyamvada for letting us borrow him ❤️
Daniele Raggi retweeted
Replying to @PGrivasMDPhD
Delighted to be part of this exciting meeting and the faculty. Will be great to catch up with you all and learn together. Please register for the meeting. @gbanna74 @ravikanesvaran @montypal @dmukherji @alison_tree @DrDarrenPoon @ParamMariappan @neerajaiims
Daniele Raggi retweeted
Please consider registering for this amazing meeting hosted by @gbanna74 & @ravikanesvaran! A terrific faculty including @dmukherji, @ProfSyedHussain, @alison_tree, @DrDarrenPoon, @ParamMariappan, @neerajaiims, @PGrivasMDPhD, @koshkin85, @DanieleRaggi83, @VanitaNoronha, @amg120395 & @MariaBarbu128! Always an amazing time w great learning. New this year - oral presentations, one of which will be delivered by my former research fellow @NickSalgia @RoswellPark!
🚨 #IUCS26 is back on Sept 3-4! Join the International Urology Cancer Summit in Guildford (UK) or online 💻
🔬 Top global experts & e-posters
🎓 8 CPD credits (in-person only)
💸 FREE registration
🎟️ Register by Sept 2: urologycancersummit.org/regi…
#Urology #Oncology #UroCan
Daniele Raggi retweeted
Congratulations to Drs. Emanuele Crupi, @emanuele_crupi Daniele Raggi @DanieleRaggi83 and colleagues on the publication of this timely article last month in Nature Reviews Urology @NatRevUrol
HER2-directed antibody - drug conjugates (ADCs) are rapidly transforming the treatment landscape of urothelial carcinoma. Landmark clinical trials have established HER2-targeted therapy as a new therapeutic pillar. However, there is urgent need for urothelial carcinoma–specific HER2 testing and interpretation criteria. Current HER2 scoring systems are largely adapted from breast and gastroesophageal cancers, despite important differences in tumor biology, staining patterns, specimen types, and intratumoral heterogeneity. These limitations can substantially influence HER2 classification, patient selection, clinical trial eligibility, and ultimately access to life-extending therapies.
The authors provide a compelling framework highlighting the need for standardized HER2 assessment, consideration of spatial and temporal heterogeneity, and future integration of dynamic biomarkers such as liquid biopsy. As HER2 ADCs become increasingly central to precision medicine in bladder cancer, achieving diagnostic clarity will be essential to fully unlocking the potential of these breakthrough therapies.
Full article link: nature.com/articles/s41585-0…
Daniele Raggi retweeted
More than 40 bispecific ADCs in the clinic!
Figure from cell.com/cancer-cell/fulltex…
@BarbaraPistill2 @FerMosele
1 now approved by China NMPA
7 with reported clinical data thus far
3 discontinued (one more after publication)
3 additional in clinical development (not in the table)
Daniele Raggi retweeted
Another win for precision medicine in prostate cancer ! Molecular / Genomic testing is a requirement for good clinical practice !
No excuses no delays and no patient left behind.
It takes a lot of such wins to stack and move the needle in our field and they are coming🙌🏻 @oncodaily @neerajaiims @scserendipity1 @OncoAlert #prostatecancer #precisionmedicine
Daniele Raggi retweeted
Delighted that our STAMPEDE paper on abiraterone therapy selection with MMAI in high risk M0 HSPC now out. kwnsfk27.r.eu-west-1.awstrac…
















































